Back to results
US 12,533,350 B2Granted
Use of melanocortin-1 receptor agonist
AssigneeTanabe Pharma Corporation
InventorsMasahiro Kondo, Tsuyoshi Suzuki, Yuko Kawano
Life of this patent
Estimating the term…
Abstract
A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject includes, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.
Claims20
A method for treating systemic sclerosis-associated interstitial lung disease, comprising:
- administering an effective amount of 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof to a subject in need thereof.
Dependencies are inferred from the claim text.